In Ireland, mesothelioma (general) is managed by oncologists. Mesothelioma is an aggressive cancer of the mesothelial cells that line the pleura, peritoneum, pericardium, or tunica vaginalis, with roughly 80% of cases linked directly to prior asbestos exposure and a typical latency of 30-40 years between exposure and diagnosis. Around 30,000 new cases occur globally each year and roughly 3,300 annually in the United States, with pleural mesothelioma accounting for 80-85% of presentations.
Mesothelioma (ICD-10: C45) is a malignant neoplasm arising from the mesothelial cells that form serosal membranes — primarily the pleura around the lungs, the peritoneum around abdominal organs, the pericardium around the heart, and the tunica vaginalis around the testes. The dominant carcinogen is asbestos, and to a lesser extent erionite and therapeutic ionizing radiation. Inhaled or ingested mineral fibers translocate to mesothelial surfaces, where they generate chronic inflammation, reactive oxygen species, and somatic mutations in tumor-suppressor genes including BAP1, NF2, CDKN2A, and TP53. Loss of BAP1 is found in roughly 60% of pleural mesotheliomas and confers an inherited susceptibility syndrome in carriers of germline BAP1 mutations.
The key symptoms of Mesothelioma (general) are: Progressive shortness of breath that develops over weeks to months, usually from a pleural effusion compressing the underlying lung — the single most common presenting symptom of pleural mesothelioma., Dull, persistent chest wall pain on the affected side that may worsen with deep breathing, coughing, or lying down, reflecting tumor invasion of the parietal pleura or chest wall., Unexplained weight loss of more than 5% of body weight over 6 months, often accompanied by fatigue and reduced appetite., Persistent dry cough that does not respond to inhalers or antibiotics, sometimes accompanied by hoarseness if the recurrent laryngeal nerve is involved., Abdominal distention, ascites, and a feeling of fullness in peritoneal mesothelioma, often misattributed to ovarian or gastrointestinal cancer at first presentation., Night sweats and low-grade fevers that mimic infection or lymphoma, present in roughly 30% of patients at diagnosis., Palpable chest wall mass at sites of previous biopsy or chest drainage — mesothelioma seeds along needle tracks in roughly 10% of untreated cases..
Diagnosis follows a stepwise pathway anchored in imaging-guided tissue sampling, because cytology alone is rarely sufficient and small biopsies are prone to misclassification. The typical patient presents with unilateral pleural effusion or chest pain; chest X-ray followed by contrast-enhanced CT chest is the first imaging step. CT findings suggestive of mesothelioma include nodular or circumferential pleural thickening (>1 cm), mediastinal pleural involvement, infiltration into fissures, and chest wall extension. Pleural effusion is drained therapeutically and cytology is sent, though cytologic diagnosis alone is positive in only 30-50% of cases and considered inadequate by 2020 ESMO and 2024 NCCN guidelines for treatment planning. The definitive diagnostic step is image-guided or thoracoscopic pleural biopsy — thoracoscopic (medical or surgical) sampling yields a diagnosis in over 90% of cases. Immunohistochemistry is essential: positive staining for calretinin, WT1, CK5/6, and D2-40 (podoplanin), with negative carcinoma markers (CEA, BerEP4, TTF-1, claudin-4), supports mesothelial origin. BAP1 loss and CDKN2A homozygous deletion (by FISH) help distinguish malignant mesothelioma from reactive mesothelial proliferation. Once diagnosed, staging includes contrast CT chest/abdomen/pelvis, PET-CT (for nodal and extrathoracic disease), and brain MRI when symptomatic. Pulmonary function tests and cardiac assessment guide surgical eligibility. For peritoneal disease, diagnostic laparoscopy with biopsy is preferred, and the Peritoneal Cancer Index (PCI) is calculated to plan cytoreductive surgery candidacy.
Mesothelioma requires multidisciplinary care at a high-volume center because diagnosis is histologically nuanced, staging guides surgical eligibility narrowly, and contemporary immunotherapy and surgical-HIPEC regimens have significant learning-curve effects. Specialists coordinate thoracic surgery, medical oncology, radiation oncology, pathology, palliative care, and clinical trial access — survival is measurably longer at specialist centers.
Find specialists →Systemic therapy is delivered over 4-6 months for first-line chemotherapy and up to 2 years for first-line immunotherapy. Pleurectomy/decortication requires 6-8 weeks for return to baseline activity, with full pulmonary recovery over 3-6 months. Peritoneal CRS-HIPEC involves 7-10 days of inpatient recovery and 4-6 weeks of restricted activity. Surveillance imaging (CT chest with or without PET) is performed every 3 months for the first 2 years, then every 6 months.
Look for a thoracic medical oncologist or surgical oncologist with mesothelioma-specific volume (at least 15-20 cases annually), institutional access to CheckMate 743-style immunotherapy regimens, on-site pleural service with thoracoscopy, and active enrollment in mesothelioma clinical trials. For peritoneal disease, seek a peritoneal-surface-malignancy center with established CRS-HIPEC programs.
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Ireland.
Apply as specialist →Specialists who treat Mesothelioma (general). Get expert guidance and personalized care.
Prognosis remains guarded but has improved meaningfully over the past decade. Historical 5-year survival for pleural mesothelioma was below 10% across all stages. With contemporary immunotherapy, median overall survival is 18.1 months in unresectable pleural disease (CheckMate 743), reaching 24-30 months in selected stage I-II epithelioid patients who complete trimodality therapy. Peritoneal mesothelioma fares better when amenable to cytoreductive surgery with HIPEC, with median survival of 53 months and 5-year survival of 47% in completely cytoreduced patients. Adverse prognostic factors include sarcomatoid histology (median survival 8-12 months), advanced stage, poor performance status, low albumin, high platelet count, and absence of surgical candidacy. Favorable factors include epithelioid histology, complete cytoreduction, BAP1-mutant tumors (paradoxically associated with longer survival), and access to immunotherapy and clinical trials. The variation across specialist centers is substantial — high-volume centers report up to 30% longer median survival, reinforcing the importance of multidisciplinary care.
Maintain regular low-to-moderate intensity activity within breathlessness tolerance. Walking 20-30 minutes most days, supervised pulmonary rehabilitation before surgery, and graded resistance training during treatment all preserve performance status and reduce treatment-related fatigue.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026